Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Other Non Operating Income of -$1.5 million for Q1 2026, up 85.97% on a QoQ basis from -$10.4 million in Q4 2025, and down 146300.0% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Other Non Operating Income history runs 16 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- Quarterly Other Non Operating Income fell 146300.0% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.0 million (down 30905.77% YoY) and the FY2025 annual result came in at -$17.3 million, changed N/A from the prior year.
- Other Non Operating Income was -$1.5 million for Q1 2026 at Biocryst Pharmaceuticals, up from -$10.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $28.0 million in Q4 2023 and bottomed at -$29.0 million in Q2 2023.
- A 5-year average of -$1.2 million and a median of -$130500.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income surged 1510.99% — and 2026, when it sank 146300.0%.
- Biocryst Pharmaceuticals' Other Non Operating Income stood at -$2.0 million in 2022, then jumped by 1510.99% to $28.0 million in 2023, then tumbled by 99.87% to $37000.0 in 2024, then slumped by 28264.86% to -$10.4 million in 2025, then surged by 85.97% to -$1.5 million in 2026.
- Business Quant data shows BCRX's Other Non Operating Income at -$1.5 million in Q1 2026, -$10.4 million in Q4 2025, and $35000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | -10.42 Mn |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | -4.17 Mn |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 37,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Jun 30, 2024 | -84,000.00 |
| Mar 31, 2024 | -51,000.00 |
| Dec 31, 2023 | 27.98 Mn |
| Jun 30, 2023 | -29.02 Mn |
| Mar 31, 2023 | -229,000.00 |
| Dec 31, 2022 | -1.98 Mn |
| Sep 30, 2022 | -538,000.00 |
| Jun 30, 2022 | 132,000.00 |
| Mar 31, 2022 | -177,000.00 |
| Dec 31, 2021 | -421,000.00 |
| Sep 30, 2021 | -111,000.00 |
| Jun 30, 2021 | -134,000.00 |
| Mar 31, 2021 | -29,000.00 |